Clinical trials: Autotransplantation
Multiple Myeloma, Plasma Cell Neoplasm
Vorinostat and Lenalidomide After Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma
RATIONALE: Vorinostat may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Lenalidomide may stop the growth of multiple myeloma by blocking blood flow to the cancer.
- Trial name
- NCT00729118
- Testing
- lenalidomide, vorinostat
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Vitiligo
Autologous Transplantation of Melanocytes for Treatment of Vitiligo Skin
The purpose of this study is to investigate the efficacy and safety of autologous transplantation of melanocytes in patients with vitiligo.
- Trial name
- NCT00631865
- Testing
- Melanocyte transplantation
- Where
- Iran
- Volunteers
- 300 people
- Sponsor
- Royan Institute
Defect of Articular Cartilage, Osteochondritis Dissecans
Cartilage Autograft Implantation System (CAIS) for the Repair of Knee Cartilage Through Cartilage Regeneration
The Cartilage Autograft Implantation System (CAIS) is designed as a single surgical treatment of damaged knee cartilage using the subject's own healthy cartilage obtained from a non-weight or low weight-bearing region.
- Trial name
- CAIS (NCT00881023)
- Testing
- Microfracture, Cartilage Autograft Implantation System
- Where
- 29 sites in United States, Canada
- Volunteers
- 75 people
- Sponsor
- DePuy Mitek
Ultra High Risk mm (uhr-mm), 18-70 Years Old, Suitable for ASCT. And Meet Any of the Following uhr-mm Definitions, Cytogenetics Ultra High Risk
Autologous Transplantation Combined With BCMA CAR-T in the Treatment of UHR-MM
To evaluate the safety and efficacy of autologous hematopoietic stem cell transplantation (ASCT) combined with BCMA-CART in the treatment of UHR-MM.
- Conditions
- Ultra High Risk mm (uhr-mm), 18-70 Years Old, Suitable for ASCT. And Meet Any of the Following uhr-mm Definitions, Cytogenetics Ultra High Risk, Primary Refractory, Early Progression
- Trial name
- NCT07109323
- Testing
- BCMA CART
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Anterior Cruciate Ligament Rupture, Donor Site Complication
BTB Graft Harvest and Donor Site Morbidity After ACL Reconstruction
The aim of this observational study is to examine the connection between bone-tendinous defects after BTB graft harvest and the development of anterior knee pain.
- Trial name
- NCT06030791
- Testing
- MRI
- Where
- Serbia
- Volunteers
- 60 people
- Sponsor
- Clinical Center of Vojvodina
Tooth Loss
Autotransplantation and Enamel Matrix Derivatives Case Series
The goal of this prospective case series is to compare the adjunctive use of enamel matrix derivatives in the treatment of tooth autotransplantation in terms of clinical attachment level.
- Trial name
- ATTCS (NCT06261255)
- Testing
- ATT + EMD
- Where
- 2 sites in Spain
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Universidad Complutense de Madrid
Anterior Cruciate Ligament Injuries
Graft Selection in Anatomic Anterior Cruciate Ligament Reconstruction
A rupture of the anterior cruciate ligament (ACL) is a severe injury of the knee. The current gold Standard treatment for young and active patients with instability, is a surgical ACL reconstruction.
- Trial name
- Grafttype (NCT03073083)
- Testing
- Hamstring tendon autograft, Pattella tendon autograft, Quadriceps tendon autograft
- Where
- 2 sites in Netherlands
- Volunteers
- 439 people
- Sponsor
- Orthopedisch Centrum Oost Nederland
Multiple Myeloma
A Phase III, Safety, Tolerability and Efficacy of Combination Treatment of BL-8040 and Granulocyte Colony Stimulating Factor (G-CSF) as Compared to Placebo and G-CSF for the Mobilization of Hematopoietic Stem Cells for Autologous Transplantation in Subjects With Multiple Myeloma (MM)
A total of 122 subjects were randomized into the study and investigated in the double-blind placebo-controlled setting to assess the efficacy and safety of G-CSF + BL-8040 as compared to G-CSF + placebo.
- Trial name
- GENESIS (NCT03246529)
- Testing
- BL-8040 1.25 mg/kg + G-CSF
- Where
- 18 sites in United States, Germany and 3 more
- Volunteers
- 180 people
- Sponsor
- BioLineRx, Ltd.
Anterior Cruciate Ligament Injury, Anterior Cruciate Ligament Reconstruction
Donor Ankle Sensorimotor Recovery After ACL Reconstruction With a Peroneus Longus Tendon Autograft
This prospective longitudinal observational cohort study will characterize recovery of donor-ankle sensorimotor function in adults who have undergone primary anterior cruciate ligament reconstruction using a peroneus longus…
- Conditions
- Anterior Cruciate Ligament Injury, Anterior Cruciate Ligament Reconstruction, Donor Site Complication
- Trial name
- NCT07762989
- Testing
- Anterior Cruciate Ligament Reconstruction Using a Peroneus Longus Tendon Autograft
- Where
- Turkey (Türkiye)
- Volunteers
- 20 people
- Sponsor
- Gazi University
Multiple Myeloma
Tandem Auto Transplantation in Myeloma Patients With <12 Months of Prior Treatment
This study is designed to decrease toxicity associated with prior tandem transplant protocols by reducing the intensity of induction, consolidation and maintenance therapy, while increasing event-free survival by adding…
- Trial name
- NCT01548573
- Testing
- Dexamethasone, Tandem autologous stem cell transplant, Cisplatin
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- University of Iowa
Multiple Myeloma
Phase I: Melphalan, Bendamustine and Carfilzomib for Autologous Transplant in Multiple Myeloma
This is a phase I clinical trial. Patients with a diagnosis of multiple myeloma undergoing autologous transplantation will receive a preparative regimen of melphalan, bendamustine, and carfilzomib.
- Trial name
- NCT02148913
- Testing
- Cohort 1: Carfilzomib 15 mg/m2, Cohort 2: Carfilzomib 20 mg/m2, Cohort 2b: Carfilzomib 20 mg/m2
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Corewell Health West
Autologous Transplant, Myeloma
Mycobiome Supporting Diet to Reduce GI Toxicity Associated With ASCT
The purpose of this study is to determine if this specific Mycobiome Supporting Diet (MSD diet) can help reduce gut inflammation during post-transplant period.
- Trial name
- NCT04685525
- Testing
- Mycobiome Supporting Diet
- Where
- United States
- Sponsor
- Case Comprehensive Cancer Center